Z

Zeiss

Corporate venture capital for deep-tech startups

Business Development Representative

Full-TimeUpdated on 10/23/2026
$82.5k/yr+ Sales commission
Mid
Bachelor's
California, USA
RemoteMust live within the Northern California territory; ideal candidate resides in Sacramento or within 20 miles.
Sales & Account ManagementField Sales
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • Three or more years in a successful business-to-business sales environment.
  • A valid driver's license.
Responsibilities
  • Meet or exceed sales growth targets for Direct Rx business and strategic targets, including premium lenses, coatings, dispensing tools and equipment, or key sales programs.
  • Segment the territory using the Customer Relationship Management Account Classification system and identify key customer targets to increase territory sales.
  • Profile and evaluate each customer's store operation, financial data, business model, and profit drivers, and create value-based sales strategies with a positive financial impact on the company.
  • Conduct and prepare pre-call planning and call objectives, anticipate likely objections, understand customer motivations, and establish relationships as a trusted advisor or consultant.
  • Lead sales conversations with eye care professionals by challenging and persuading them to change behavior, building agreement throughout the sales process, removing barriers, and closing deals.
  • Create tactical and strategic approaches to meet and exceed business objectives when faced with obstacles or customer concerns.
  • Create and execute a territory plan to achieve goals, considering required investment and financial impact when developing customer strategies.
  • Increase sales by communicating the advantages and benefits of Carl Zeiss Vision products and services to eye care professionals.
  • Support and implement national marketing plans using digital tools and apps.
  • Schedule, plan, develop, and conduct on-site individual, group, and office training and educational seminars to increase demand for Carl Zeiss Vision labs, lenses, and dispensing tools.
  • Execute customer marketing programs to accomplish goals and objectives.
  • Establish positive, productive, and collaborative working relationships with Carl Zeiss Vision employees and colleagues.
  • Operate ethically during every customer interaction and in alignment with Carl Zeiss philosophies and leadership principles.
  • Input accurate and timely reports via Salesforce.com.
  • Manage travel costs efficiently and use smart spending techniques.
  • Prepare and submit expense reports in a timely manner.
Desired Qualifications
  • A BS or BA in Business, Public Administration, Economics, Marketing, or a related field is strongly preferred.
  • Experience in Rx sales, optical, medical device, or retail operations, preferably with Fortune 500 companies.
  • Strong sales focus and ability to move key opportunities through the sales cycle, provide accurate sales forecasts, and use the company's Customer Relationship Management tool.
  • Ability to thrive in a competitive environment.
  • Experience creating plans to achieve revenue and profitability goals.
  • Consultative, conceptual, and negotiation skills, with ability to establish influential customer relationships.
  • Disciplined, results-oriented approach to selling and strong time management skills.
  • Ability to work collaboratively with others.
  • Ability to influence situations and people.
  • Ability to work independently as a self-starter.
  • ABO and ABO speaker certification.
  • Verbal and written communication skills.
  • Interpersonal, problem-solving, and analytical skills.
  • Proficiency with standard Microsoft Office applications and company technology devices, including laptop, iPad, and iPhone, for territory management and product orders; knowledge of Salesforce.com.

About the company

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
  • ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
  • EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.

What critics are saying

  • ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
  • Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
  • ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.

What makes Zeiss unique

  • ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
  • ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
  • ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Performance Bonus

Company News

Associated Press
Oct 12th, 2026
ZEISS launches NLX X-ray inspection and DUNE wafer warpage correction for advanced chip packaging

ZEISS Semiconductor Manufacturing Technology (SMT) has launched two systems for advanced chip packaging: ZEISS NLX and ZEISS DUNE. The company announced them in San Francisco on October 12, 2026, as chips grow more complex. ZEISS NLX inspects the inside of chip packages without damaging them. It helps manufacturers spot defects in connections between stacked dies early, and it handles 300-millimetre wafers in both process development and high-volume production. ZEISS DUNE measures the topography of a wafer and corrects wafer bow individually. This helps avoid yield losses in downstream processing and prepares bonding processes. ZEISS SMT is showing the systems at SEMICON West, alongside its photomask tools. The company is also marking 100 years of business in the US in 2026.

PR Newswire
Sep 24th, 2026
ZEISS unveils retinal imaging and surgical innovations at EURETINA 2026

ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.

PR Newswire
Sep 17th, 2026
ZEISS expands retinal imaging portfolio with new ALTA DUO 300 multimodal OCT device

ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.